Humoral immune response to SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases.

Background: Patients with autoimmune rheumatic diseases (ARD) are at increased risk of infection due to their impaired immune response, which also reduces vaccination efficacy. Although several studies have evaluated the serological response to SARS-CoV-2 mRNA-based vaccines in patients with ARD, limited information on immune responses to other vaccination platforms is available.

Aims: This observational prospective study aims to investigate the humoral immune response to different SARS-CoV-2 vaccines in patients with ARD.

Danger Biomarkers in Perfusates From Fatty Liver Grafts Subjected to Cold Storage Preservation in Different Preservation Solutions.

Static cold storage remains the traditional standard for liver graft preservation prior to transplantation in both clinical and experimental settings. The use of polyethylene glycol 35 solutions, such as Institut Georges Lopez-2 (IGL2) preservation solution, for protecting against mitochondrial damage during cold static preservation necessitates combination with hypothermic oxygenated perfusion to enhance liver graft performance. This study presents a preliminary comparative evaluation of "danger signals" indicating hepatocellular injury (transaminases, lactate content), mitochondrial damage (glutamate dehydrogenase release), and cytokine release in liver perfusates from suboptimal grafts (fatty livers) subjected to 24-hour cold storage.

Altered mitochondria-associated ER membrane (MAM) function shifts mitochondrial metabolism in amyotrophic lateral sclerosis (ALS).

Mitochondrial function is modulated by its interaction with the endoplasmic reticulum (ER). Recent research indicates that these contacts are disrupted in familial models of amyotrophic lateral sclerosis (ALS). We report here that this impairment in the crosstalk between mitochondria and the ER impedes the use of glucose-derived pyruvate as mitochondrial fuel, causing a shift to fatty acids to sustain energy production.

Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016.

Background: The advent of disease-modifying treatments (DMT) has changed natural history in 5q Spinal muscular atrophy (SMA). The aim of this study was to report survival and functional aspects in all the Italian type I children born since 2016.

Methods: The study included all symptomatic children with type I SMA born since January 1st, 2016, when DMTs became available in Italy.